CA3219851A1 - Method of treating patients with hepatorenal syndrome type 1 - Google Patents
Method of treating patients with hepatorenal syndrome type 1 Download PDFInfo
- Publication number
- CA3219851A1 CA3219851A1 CA3219851A CA3219851A CA3219851A1 CA 3219851 A1 CA3219851 A1 CA 3219851A1 CA 3219851 A CA3219851 A CA 3219851A CA 3219851 A CA3219851 A CA 3219851A CA 3219851 A1 CA3219851 A1 CA 3219851A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- terlipressin
- baseline
- hrs
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000011200 hepatorenal syndrome Diseases 0.000 title claims abstract description 168
- 238000000034 method Methods 0.000 title claims abstract description 147
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 claims abstract description 517
- 108010010056 Terlipressin Proteins 0.000 claims abstract description 479
- 229960003813 terlipressin Drugs 0.000 claims abstract description 479
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims abstract description 216
- 238000011282 treatment Methods 0.000 claims abstract description 152
- 229940109239 creatinine Drugs 0.000 claims abstract description 108
- 210000002966 serum Anatomy 0.000 claims abstract description 100
- 208000010334 End Stage Liver Disease Diseases 0.000 claims abstract description 35
- 208000011444 chronic liver failure Diseases 0.000 claims abstract description 35
- 206010057573 Chronic hepatic failure Diseases 0.000 claims abstract description 34
- 238000012544 monitoring process Methods 0.000 claims abstract description 24
- 238000006213 oxygenation reaction Methods 0.000 claims abstract description 10
- 208000019423 liver disease Diseases 0.000 claims abstract description 8
- 238000001990 intravenous administration Methods 0.000 claims description 110
- 230000004044 response Effects 0.000 claims description 98
- 238000002347 injection Methods 0.000 claims description 67
- 239000007924 injection Substances 0.000 claims description 67
- 208000002467 Acute-On-Chronic Liver Failure Diseases 0.000 claims description 51
- 230000004083 survival effect Effects 0.000 claims description 50
- 230000001965 increasing effect Effects 0.000 claims description 44
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims description 40
- 230000006872 improvement Effects 0.000 claims description 40
- 201000004193 respiratory failure Diseases 0.000 claims description 40
- 210000004185 liver Anatomy 0.000 claims description 32
- 206010016803 Fluid overload Diseases 0.000 claims description 31
- 230000002411 adverse Effects 0.000 claims description 30
- 230000007423 decrease Effects 0.000 claims description 30
- 230000003247 decreasing effect Effects 0.000 claims description 21
- 230000036961 partial effect Effects 0.000 claims description 17
- 206010037423 Pulmonary oedema Diseases 0.000 claims description 15
- 208000005333 pulmonary edema Diseases 0.000 claims description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 14
- 239000001301 oxygen Substances 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 239000002934 diuretic Substances 0.000 claims description 11
- 206010021143 Hypoxia Diseases 0.000 claims description 10
- 230000007954 hypoxia Effects 0.000 claims description 10
- 208000017169 kidney disease Diseases 0.000 claims description 10
- 229940030606 diuretics Drugs 0.000 claims description 9
- 230000001010 compromised effect Effects 0.000 claims description 8
- 208000000059 Dyspnea Diseases 0.000 claims description 7
- 206010013975 Dyspnoeas Diseases 0.000 claims description 7
- 238000002106 pulse oximetry Methods 0.000 claims description 6
- 206010062237 Renal impairment Diseases 0.000 abstract description 7
- 231100000857 poor renal function Toxicity 0.000 abstract description 6
- 239000000902 placebo Substances 0.000 description 87
- 229940068196 placebo Drugs 0.000 description 87
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 76
- 238000012959 renal replacement therapy Methods 0.000 description 51
- 108010088751 Albumins Proteins 0.000 description 35
- 102000009027 Albumins Human genes 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 35
- 208000015181 infectious disease Diseases 0.000 description 34
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 31
- 210000000265 leukocyte Anatomy 0.000 description 31
- 208000019425 cirrhosis of liver Diseases 0.000 description 28
- 206010016654 Fibrosis Diseases 0.000 description 27
- 230000007882 cirrhosis Effects 0.000 description 27
- 206010040047 Sepsis Diseases 0.000 description 25
- 230000003907 kidney function Effects 0.000 description 21
- 230000009467 reduction Effects 0.000 description 20
- 230000002829 reductive effect Effects 0.000 description 18
- 206010040070 Septic Shock Diseases 0.000 description 17
- 230000036303 septic shock Effects 0.000 description 17
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 14
- 206010003445 Ascites Diseases 0.000 description 13
- 230000000116 mitigating effect Effects 0.000 description 13
- 201000006370 kidney failure Diseases 0.000 description 12
- 238000002054 transplantation Methods 0.000 description 12
- 208000001647 Renal Insufficiency Diseases 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000000977 initiatory effect Effects 0.000 description 11
- 238000004820 blood count Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 230000000302 ischemic effect Effects 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 206010035664 Pneumonia Diseases 0.000 description 7
- 229910002092 carbon dioxide Inorganic materials 0.000 description 7
- 239000001569 carbon dioxide Substances 0.000 description 7
- 230000001747 exhibiting effect Effects 0.000 description 7
- 230000029058 respiratory gaseous exchange Effects 0.000 description 7
- 208000009079 Bronchial Spasm Diseases 0.000 description 6
- 208000014181 Bronchial disease Diseases 0.000 description 6
- 206010006482 Bronchospasm Diseases 0.000 description 6
- 230000007717 exclusion Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 230000000241 respiratory effect Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 230000024883 vasodilation Effects 0.000 description 6
- 206010053159 Organ failure Diseases 0.000 description 5
- 206010047139 Vasoconstriction Diseases 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 230000025033 vasoconstriction Effects 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 108010048179 Lypressin Proteins 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical class C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 208000007386 hepatic encephalopathy Diseases 0.000 description 4
- 238000004750 isotope dilution mass spectroscopy Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000010837 poor prognosis Methods 0.000 description 4
- 230000008718 systemic inflammatory response Effects 0.000 description 4
- 208000008203 tachypnea Diseases 0.000 description 4
- 206010043089 tachypnoea Diseases 0.000 description 4
- 208000009304 Acute Kidney Injury Diseases 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 206010022680 Intestinal ischaemia Diseases 0.000 description 3
- 208000033626 Renal failure acute Diseases 0.000 description 3
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 3
- 108010004977 Vasopressins Proteins 0.000 description 3
- 102000002852 Vasopressins Human genes 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 201000011040 acute kidney failure Diseases 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000002924 anti-infective effect Effects 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000024924 glomerular filtration Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 208000007232 portal hypertension Diseases 0.000 description 3
- 230000036387 respiratory rate Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 229960003726 vasopressin Drugs 0.000 description 3
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 2
- PTKSEFOSCHHMPD-SNVBAGLBSA-N 2-amino-n-[(2s)-2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide Chemical compound COC1=CC=C(OC)C([C@H](O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-SNVBAGLBSA-N 0.000 description 2
- 208000007788 Acute Liver Failure Diseases 0.000 description 2
- 206010011703 Cyanosis Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- UXIGWFXRQKWHHA-UHFFFAOYSA-N Iotalamic acid Chemical compound CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I UXIGWFXRQKWHHA-UHFFFAOYSA-N 0.000 description 2
- 238000007375 Jaffe assay Methods 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- -1 N-glycylglycyl Chemical group 0.000 description 2
- XEYWFABKOXWUSY-UHFFFAOYSA-N O.O.O.O.O.C(C)(=O)O.C(C)(=O)O Chemical compound O.O.O.O.O.C(C)(=O)O.C(C)(=O)O XEYWFABKOXWUSY-UHFFFAOYSA-N 0.000 description 2
- 108010016076 Octreotide Proteins 0.000 description 2
- 206010062070 Peritonitis bacterial Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 230000036757 core body temperature Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 2
- 229960001025 iohexol Drugs 0.000 description 2
- 229940029378 iothalamate Drugs 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 229960001094 midodrine Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229960002700 octreotide Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940075930 picrate Drugs 0.000 description 2
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009325 pulmonary function Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000007430 reference method Methods 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- BJFIDCADFRDPIO-DZCXQCEKSA-N (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)-1,2-dithia-5,8,11,14,17-pentazacycloeicos-4-yl]-oxomethyl]-2-pyrrolidinecarboxamide Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1 BJFIDCADFRDPIO-DZCXQCEKSA-N 0.000 description 1
- 101100339677 Arabidopsis thaliana HRS1 gene Proteins 0.000 description 1
- OXDZADMCOWPSOC-UHFFFAOYSA-N Argiprestocin Chemical class N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 OXDZADMCOWPSOC-UHFFFAOYSA-N 0.000 description 1
- 206010003504 Aspiration Diseases 0.000 description 1
- 206010070545 Bacterial translocation Diseases 0.000 description 1
- 206010072081 Bandaemia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 206010059028 Gastrointestinal ischaemia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020660 Hyperlactacidaemia Diseases 0.000 description 1
- 208000005018 Hyperlactatemia Diseases 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 206010024648 Livedo reticularis Diseases 0.000 description 1
- 208000004535 Mesenteric Ischemia Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000036576 Obstructive uropathy Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010036155 Poor peripheral circulation Diseases 0.000 description 1
- 101100129874 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PGD1 gene Proteins 0.000 description 1
- 101100129591 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mcp6 gene Proteins 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000026349 Vascular skin disease Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 108010041332 Very Late Antigen Receptors Proteins 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940124572 antihypotensive agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000007375 bacterial translocation Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical class 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000013531 gin Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229960003837 lypressin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000013349 risk mitigation Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000037370 skin discoloration Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/340,765 US20210290725A1 (en) | 2014-10-24 | 2021-06-07 | Method of treating patients with hepatorenal syndrome type 1 |
| US17/340,765 | 2021-06-07 | ||
| PCT/US2022/032511 WO2022261102A1 (en) | 2021-06-07 | 2022-06-07 | Method of treating patients with hepatorenal syndrome type 1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3219851A1 true CA3219851A1 (en) | 2022-12-15 |
Family
ID=84426322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3219851A Pending CA3219851A1 (en) | 2021-06-07 | 2022-06-07 | Method of treating patients with hepatorenal syndrome type 1 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4351619A1 (zh) |
| KR (1) | KR20240019089A (zh) |
| CN (1) | CN117425488A (zh) |
| AU (1) | AU2022288996A1 (zh) |
| BR (1) | BR112023023894A2 (zh) |
| CA (1) | CA3219851A1 (zh) |
| WO (1) | WO2022261102A1 (zh) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8628979B2 (en) * | 2009-10-21 | 2014-01-14 | Pronota N.V. | MCAM as a biomarker for fluid homeostasis |
| US20210000385A1 (en) * | 2014-04-11 | 2021-01-07 | Halare, Inc. | Systems, methods and apparatuses for monitoring hypoxic events |
| US20210290725A1 (en) * | 2014-10-24 | 2021-09-23 | Mallinckrodt Pharmaceuticals Ireland Limited | Method of treating patients with hepatorenal syndrome type 1 |
| US20200261443A1 (en) * | 2019-02-15 | 2020-08-20 | Martin Pharmaceuticals Inc. | Use of Anti-Ischemic Compounds in Treating Acute-On-Chronic Liver Failure |
| BR112022006329A2 (pt) * | 2019-10-30 | 2022-08-16 | Mallinckrodt Hospital Products IP Unlimited Company | Método de tratamento de pacientes com síndrome hepatorrenal tipo 1 e pressão arterial média baixa |
-
2022
- 2022-06-07 AU AU2022288996A patent/AU2022288996A1/en active Pending
- 2022-06-07 BR BR112023023894A patent/BR112023023894A2/pt unknown
- 2022-06-07 EP EP22820898.9A patent/EP4351619A1/en active Pending
- 2022-06-07 KR KR1020237040067A patent/KR20240019089A/ko unknown
- 2022-06-07 CA CA3219851A patent/CA3219851A1/en active Pending
- 2022-06-07 CN CN202280040420.5A patent/CN117425488A/zh active Pending
- 2022-06-07 WO PCT/US2022/032511 patent/WO2022261102A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240019089A (ko) | 2024-02-14 |
| EP4351619A1 (en) | 2024-04-17 |
| CN117425488A (zh) | 2024-01-19 |
| AU2022288996A1 (en) | 2023-11-30 |
| BR112023023894A2 (pt) | 2024-02-20 |
| WO2022261102A1 (en) | 2022-12-15 |
| AU2022288996A9 (en) | 2023-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7346494B2 (ja) | １型肝腎症候群患者の治療方法 | |
| EA037823B1 (ru) | Способ лечения субъекта, испытывающего интенсивный шок и получающего лечение катехоламином или вазопрессином | |
| US20210290725A1 (en) | Method of treating patients with hepatorenal syndrome type 1 | |
| Jochberger et al. | Course of vasopressin and copeptin plasma concentrations in a patient with severe septic shock | |
| US20200237856A1 (en) | Method of treating patients with hepatorenal syndrome type 1 | |
| US20210128676A1 (en) | Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure | |
| CA3219851A1 (en) | Method of treating patients with hepatorenal syndrome type 1 | |
| US20200246418A1 (en) | Method of treating patients with hepatorenal syndrome type 1 | |
| US20240156895A1 (en) | Compositions for improving kidney function in patients with hepatorenal syndrome | |
| US20060263358A1 (en) | Method for reducing sepsis or cardiogenic shock associated with myocardial injury | |
| WO2022029499A1 (en) | Methods of treating refractory ascites | |
| JP2014162789A (ja) | 羊水塞栓症治療剤 |